Corporate Information – Page 8 – ASCELIA

All All press releases Regulatory press releases Financial reports

2019-09-11 | Ascelia Pharma to present at Redeye seminar in Malmö on 12 September 2019

2019-09-06 | Ascelia Pharma to present at Share Day (Aktiedagen) in Stockholm on 10 September 2019

2019-08-20 | Invitation to presentation of Ascelia Pharma’s Q4 report 2018/2019

Regulatory

2019-06-10 | Ascelia Pharma strengthens its Mangoral franchise by filing of a patent application for next generation Mangoral product

2019-05-20 | Ascelia Pharma to present at Avanza börsdag, 22 May 2019

2019-05-15 | Fully financed Phase III program for Mangoral through the IPO

2019-05-13 | Ascelia Pharma to host teleconference for presentation of interim financial report

Regulatory

2019-05-10 | Nomination Committee appointed for AGM 2019 in Ascelia Pharma AB

Regulatory

2019-05-07 | Ascelia Pharma received supportive feedback from EMA on the phase 3 program for Mangoral®

Regulatory

2019-04-08 | Encouraging results from the Phase I combination study with Oncoral and oral capecitabine published in the journal Cancer Chemotherapy and Pharmacology

2018-11-19 | Ascelia Pharma receives positive feedback from FDA on design of the pivotal Phase 3 study with Mangoral®

2018-11-13 | Encouraging results from clinical Phase I study of Oncoral presented in a new publication

2018-10-23 | Oncoral demonstrates encouraging results in clinical phase I

Regulatory

2018-09-14 | Carl Bjartmar appointed as new Chief Medical Officer for Ascelia Pharma

2018-09-10 | Oncoral phase 1 results to be presented at ESMO congress in Munich

Regulatory

2017-11-13 | Oncology-focused Ascelia Pharma strengthens its board of directors to support international expansion

2017-09-14 | Ascelia Pharma strengthens its oncology product portfolio